Compare Globus Medical Inc. Class A Common Stock (GMED) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs MasterCard Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while MasterCard Inc trades at $604 (market cap $529.81B). The key difference: MasterCard Inc is far larger — about 51.7× Globus Medical Inc. Class A Common Stock's market cap, and MasterCard Inc pays a 0.58% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and MasterCard Inc for 135 Days on average.
| GMED | MA | |
|---|---|---|
Market Cap | $10.25B | $529.81B |
Volume | 1,108,124 | 3,710,695 |
Sector | Health | Financials |
52-Week High | $96.82 | $604.80 |
52-Week Low | $58.33 | $471.55 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $9.76B | $542.84B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Mastercard (MA) trades at $603.24, up 1.37% on the day, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent revenue growth from $22.2B in 2022 to $32.8B in 2025, net income margins above 45%, and three consecutive quarterly earnings beats. Institutional buying activity remains strong, with multiple funds increasing positions in Q4 2025.
Outlook remains positive with 80% analyst buy ratings and $668.67 consensus price target, representing 11% upside. Key risks include payment industry disruption from stablecoins and AI-driven competitors, though Mastercard's aggressive innovation strategy and expanding digital inclusion initiatives provide growth catalysts. The stock trades near resistance at $603 with support at $591.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
